Henry Geoffrey McMillan

IS Pharma Plc engages in development and commercial exploitation of healthcare products. The company develops, acquires and commercializes late stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Its products are Aloxi, aquoral, ContiSol, Cryogesic, Dermogesic, episil, Micelle Nanotechnology, Mysoline, OptiFlo and Variquel/Haemopressin. The company is headquartered in Chester, the United Kingdom.

IS Pharma Plc engages in development and commercial exploitation of healthcare products. The company develops, acquires and commercializes late stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Its products are Aloxi, aquoral, ContiSol, Cryogesic, Dermogesic, episil, Micelle Nanotechnology, Mysoline, OptiFlo and Variquel/Haemopressin. The company is headquartered in Chester, the United Kingdom.

IS Pharma Plc engages in development and commercial exploitation of healthcare products. The company develops, acquires and commercializes late stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Its products are Aloxi, aquoral, ContiSol, Cryogesic, Dermogesic, episil, Micelle Nanotechnology, Mysoline, OptiFlo and Variquel/Haemopressin. The company is headquartered in Chester, the United Kingdom.

IS Pharma Plc engages in development and commercial exploitation of healthcare products. The company develops, acquires and commercializes late stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Its products are Aloxi, aquoral, ContiSol, Cryogesic, Dermogesic, episil, Micelle Nanotechnology, Mysoline, OptiFlo and Variquel/Haemopressin. The company is headquartered in Chester, the United Kingdom.